STOCK TITAN

Precigen (NASDAQ: PGEN) shares Q3 results update with investors online

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Precigen, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025. The press release, dated November 13, 2025, is included as Exhibit 99.1 and relates to the company’s results of operations and financial condition for that quarter. The company notes that this information, including the exhibit, is being furnished rather than filed, which affects how it is treated under securities laws.

Positive

  • None.

Negative

  • None.
false 0001356090 0001356090 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2025

 

Precigen, Inc.
(Exact name of registrant as specified in its charter)

 

Virginia   001-36042   26-0084895
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

20374 Seneca Meadows Parkway, Germantown, Maryland 20876
(Address of principal executive offices) (Zip Code)

 

(301) 556-9900
(Registrant’s telephone number, including area code)

 

N/A
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
Common Stock, No Par Value   PGEN   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

Item 2.02.  Results of Operations and Financial Condition.

 

Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated November 13, 2025, reporting its financial results for the quarter ended September 30, 2025.

 

This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.   Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit 

No. 

  Description
     
99.1   Press release dated November 13, 2025
     
104   Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Precigen, Inc.
     
     
  By: /s/ Donald P. Lehr
    Donald P. Lehr
    Chief Legal Officer

 

Dated: November 13, 2025

 

 

FAQ

What did Precigen (PGEN) report in this 8-K filing?

Precigen furnished a press release as Exhibit 99.1 reporting its financial results for the quarter ended September 30, 2025, under the results of operations and financial condition item.

Which period’s results are covered in Precigen’s latest update for PGEN?

The update covers Precigen’s financial results for the quarter ended September 30, 2025, as described in the press release attached as Exhibit 99.1.

How is the financial information in Precigen’s press release treated under securities laws?

Precigen states that the information in the press release and the exhibit is deemed furnished, not filed, under the Securities Exchange Act of 1934, unless later specifically incorporated by reference.

What exhibits are included in this Precigen (PGEN) 8-K?

The 8-K includes Exhibit 99.1, a press release dated November 13, 2025, and Exhibit 104, the cover page interactive data file formatted as inline XBRL.

Who signed the Precigen (PGEN) 8-K current report?

The report was signed on behalf of Precigen, Inc. by Donald P. Lehr, who is the company’s Chief Legal Officer.
Precigen Inc

NASDAQ:PGEN

PGEN Rankings

PGEN Latest News

PGEN Latest SEC Filings

PGEN Stock Data

1.74B
154.71M
Biotechnology
Pharmaceutical Preparations
Link
United States
GERMANTOWN